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Two main reasons motivated us to develop a new bioinformatics pipeline to search for early 
biomarkers of BE malignant progression using publicly available transcriptome microarray 
data. First, while several datasets on BE are in the public domain, none of them 
simultaneously contained samples from EA, P-BE and nonP-BE that could be directly 
compared. This issue required us to merge the existing samples from distinct datasets and 
compare them by DEA. However, inter-dataset DEA is very sensitive to technical noise. 
Methods such as ComBat and SVA remove batch-associated noise (reviewed in (1)) but due 
to the reduced number of available BE samples these methods also removed most of the 
meaningful biological signal. To better deal with the inter-dataset noise and to take advantage 
of genes with bimodal expression, which are in principle more easily translated to protein 
level differences and thus the ideal biomarker candidates, we included the Gene Expression 
Barcode 2.0 binarization algorithm developed by McCall et al. (2, 3). The produced barcodes 
are very robust against random sources of noise because their calculation relies on the usage 
of a large amount of annotated public data as a reference to binarize the expression of each 
gene (1=expressed, 0=not expressed) per individual sample.  
In the context of our pipeline framework (S1 Fig), we curated three publicly available 
datasets of BE data on the Affymetrix HG-133A GeneChip® microarray platform. Overall, 
these three datasets contained a total of 33 BE samples. Samples described as collected in the 
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context of a clinically diagnosed EA (4) were assigned to the P-BE group (n=8) and samples 
not associated with EA at the time of analysis (5, 6) were assigned to the nonP-BE group 
(n=25). After frozen robust multi-array (fRMA) sample normalization (2, 3) we verified that 
individual samples in the merged set displayed highly correlated expression profiles 
(Parson’s correlation mean=0.92, min=0.80) (S2 Fig). This is indicative that despite the three 
distinct data sources and associated batch noise, the biological signal of BE samples was very 
comparable.  
We next identified differential gene expression (DGE) between P-BE and nonP-BE samples 
using a Bayesian DEA, as illustrated in S1 Fig C. Under the very conservative statistical 
criteria logarithm of the odds (Lods)≥5, probability DGE>99.33%) and a false discovery rate 
(FDR) of 3.9×10-5 for DGE, we identified 958 independent probe sets mapping to 799 
unique ENTREZ id genes (S3 Table). Among the unique genes, we have found up-regulation 
for 442 (S1 Fig C) and down-regulation for 357 genes. The 799 genes are able to correctly 
segregate P-BE from nonP-BE samples (S3 Fig A). As anticipated (see Materials and 
Methods section), no significant probe sets were found after testing of EA samples across 
distinct datasets (Kimchi et al. (4) vs. Watts et al. (6)). Barcode binarization of fRMA 
normalized BE and EA data (S1 Fig D) and the subsequent intersection of P-BE and nonP-
BE barcodes allowed us to find a set of 148 probe sets (S4 Table) expressed in the P-BE 
samples (barcode=1) but oppositely marked as non-expressed (barcode=0) in the nonP-BE 
samples (S1 Fig E). To find candidates more likely associated with malignancy we assumed 
that P-BE-specific probe sets should overlap with probe sets expressed in EA (barcode=1). 
Thus, we have next intersected the 148 and 1195 probe sets, respectively from P-BE and EA 
barcodes. This procedure resulted in the filtering of malignancy- linked barcode candidates to 
40 probe sets, corresponding to 38 unique genes (S1 Fig F), up-regulated in P-BE and EA 
samples as compared to nonP-BE samples. To maximize the discovery of BE early 
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progression biomarkers that most likely could be translated into routine clinical practice, we 
defined our top candidates as genes up-regulated according to DGE results and with barcode 
values set to 1 (S1 Fig G). With this final step we slimed down the final list of candidates to 
20 probe sets, corresponding to 19 unique genes over-expressed in P-BE (S1 Fig H). 
Systems biology approach for biomarker prioritization  
To improve biomarker prioritization we thought of integrating biological functions of filtered 
genes with functions potentially relevant for BE malignant progression, by uncovering the 
gene GO-BP categories over-represented among the 19 filtered biomarkers. First, we used a 
guilt-by-association GeneMANIA tool (7) to build a functional association network between 
the set of 19 genes and 100 network neighbors (S6 Fig A). Secondly we used all network 
players to evaluate the enriched GO-BP categories by GSEA. We have used this alternative 
strategy instead of directly applying GSEA to the set of 19 genes due its reduced number. 
GSEA on GeneMania network genes (biomarkers and neighbors) highlighted that the 
significant (FDR<0.05) GO-BP top categories related with cell adhesion/motility, 
inflammation, differentiation/wounding, vasculature development, extracellular-matrix and 
response to stimulus among others (S6 Fig B, S5 Table).  
To further increase the odds of success of downstream validation efforts, we have used 
knowledge-driven biomarker prioritization criteria. To be included, candidates must be 
functionally linked to 1) top biological functions detected by GSEA and to 2) phenotype 
features that characterizes BE (e.g. differentiation/wounding responses) and finally 3) 
candidates must have been previously associated to cancer progression in other tumors. Thus, 
we have searched the literature for functional characterization of the set of 19 ge nes and 
selected two potential biomarkers for proof-of-principle experimental validation. CYR61 
(alias CCN1) was the most significantly over-expressed gene in our DGE analysis (S3 Table) 
and according to barcode analysis is expressed in >93 % of EA samples. Its over-expression 
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is involved in the malignant progression and prognosis of major tumors (breast, prostate, 
colorectal and others outlined in Table 1). CYR61 was recently identified in the context of 
breast cancer (8) as a downstream target of WWTR1 (a lias TAZ), one of the barcode and 
differentially expressed genes. TAZ up-regulation is also implicated in the progressive 
phenotype of malignant tumors such as breast, colorectal and glioma, among others (Table 1) 
and was expressed according to barcode in 87% of the EA tumors in our dataset. In addition 
to CYR61, six other TAZ downstream target genes (SPARC, IER3, JUN, ACTN1, COL4A1, 
PPAP2B) were significantly enriched (P-value=2.2×10-4) among our group of 19 candidates 
(S7 Fig A), suggesting that specific pathways where CYR61, TAZ and likely other 
functionally- linked genes operate are deregulated during BE-associated EA progression. To 
further test this functional link hypothesis we explored CYR61 and TAZ interacting genes 
with gene GeneMania networking algorithm (S7 Fig B). Among network genes we identified 
barcode genes (e.g. FOS, JUN, LAMC1), significantly up-regulated genes (e.g. TEAD3, 
FOSB, ATF3) of which some are TAZ downstream targets (e.g. CTFG, JUN, EGR1). 
Analysis of top GO-BP categories (FDR<0.01) over-represented among CYR61, TAZ and 
neighbors (S7 Fig C) pointed to biological functions involving cell adhesion/migration, 
transcription and response to stimulus (S6 Table). One hypothesis suggested by the data is 
that P-BE samples have deregulated transcriptional responses to diverse stimuli, including an 
up-regulation of cell adhesive and migratory properties which will ultimately contribute to 
the malignant phenotype of BE cells.  
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